TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower NRF2 levels in oligodendrocytes—the cells that maintain myelin—with abnormal myelin and loss of large nerve fibers in people who experienced faster cognitive decline. Mouse experiments support a possible causal role, but the findings do not show that an NRF2-targeting drug prevents cognitive decline in older adults.
Researchers report that oligodendrocytes, brain cells that maintain the protective coating around nerve fibers, may contribute to age-related cognitive decline when they become dysfunctional. In a study published in Nature Medicine, human brain tissue findings and experiments in mice linked reduced activity of the protective protein NRF2 in these cells to abnormal myelin, loss of large nerve fibers and changes in cognitive performance.
The human findings drew on the Lothian Birth Cohort 1936, whose members have had cognitive abilities tracked from childhood into old age. Between ages 70 and 82, participants were assessed on memory, information-processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional testing after age 70; nearly all experienced some decline, although the pace differed.
Researchers examined brain tissue collected after death from a subset of participants. Those who had experienced greater decline tended to have fewer large nerve fibers and an abnormal buildup of myelin, the insulating material that helps electrical signals travel along nerve fibers. These tissue features were associated with the rate of cognitive change, not simply a person’s test performance at one age.
The team also found lower levels of NRF2 in oligodendrocytes among people with more severe decline. In mice, selectively reducing NRF2 in these cells produced excess myelin and loss of large nerve fibers resembling changes seen in human tissue. The mice also showed reduced improvements in cognitive performance as they aged. The animal experiments support a possible direct role for NRF2 loss, but do not establish that the same mechanism explains cognitive decline in people.
Why Myelin-Maintaining Cells Matter
The study challenges the assumption that oligodendrocytes are always protective. These cells normally produce and maintain myelin, but the findings suggest that age-related dysfunction could undermine nerve fibers rather than support them. That offers researchers a potential way to investigate how changes in brain structure relate to the pace of cognitive decline.
The results also point to NRF2 as a possible therapeutic target. The pathway is already targeted by drugs used for other neurological conditions, including multiple sclerosis. However, a biological target and a promising result in mice are not evidence that an existing medicine will preserve memory or thinking in older adults. Clinical research would be needed to test safety and benefit for this purpose.
NRF2 supplement for cognitive health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The research was led by scientists from the University of Edinburgh and the UK Dementia Research Institute. The Lothian cohort’s long record of cognitive testing gave the team a way to compare later-life brain tissue findings with changes in thinking measured over time, rather than relying only on a single test.
Researchers then used mouse experiments to probe whether reduced NRF2 in oligodendrocytes could produce related brain changes. The source report notes that NRF2-targeting medicines are used for other conditions and that earlier research has found cognitive benefits from increasing NRF2 activity in people with multiple sclerosis. Those findings concern a different patient group and do not establish effectiveness against age-related decline.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Treatment Benefits Remain Untested
The study does not show that reduced NRF2 is the sole cause of cognitive decline, or that increasing its activity will prevent or reverse it in older people. The human tissue findings are associations, while the experiments that manipulated NRF2 were conducted in mice. The source report does not provide evidence from a clinical trial of an NRF2-targeting medicine for age-related cognitive decline.
It also remains unclear which people might benefit, when any treatment would need to be given, and whether changing the pathway would be safe and effective for this purpose. The supplied report does not specify a drug, dose or timeline for human testing. The findings identify a research direction, not a treatment recommendation.
Testing NRF2 in Older Adults
Further research will need to establish whether the pathway can be safely targeted in older adults and whether doing so protects myelin, nerve fibers or cognitive abilities. That would require studies beyond the cohort tissue analysis and mouse experiments, including clinical trials designed to measure meaningful cognitive outcomes.
For now, the reported advance is the identification of oligodendrocyte dysfunction and NRF2 as potential parts of the biology behind age-related cognitive change. Whether existing medicines can be adapted for this purpose, and whether they would help, remains to be determined.
Key Questions
Which brain cells are implicated in the study?
The researchers focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular defenses and normal cell function. The study found lower NRF2 levels in oligodendrocytes among people with more severe cognitive decline.
Does the research prove that NRF2-targeting drugs prevent cognitive decline?
No. The study reports human tissue associations and mouse experiments, not a clinical trial showing that these drugs prevent age-related cognitive decline in people.
What did researchers observe in the human brain tissue?
In a subset of cohort participants, greater cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes.
What happens next?
Researchers need to test whether targeting NRF2 can safely protect brain function in older adults. The report does not specify a clinical trial or a timetable for that work.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
